Fig. 2.

The 5-HT_2CR agonists lorcaserin and CP-809,101 dose-dependently decrease ASs. (A) Representative EEG traces for GAERS injected i.p. with vehicle, 3 mg/kg CP-809,101 and 3 mg/kg CP-809,101 following pre-treatment with SB242084 (0.5 mg/kg, i.p.) (interruption in each trace indicates time of injection). Dose response curve of CP-809,101 at 0.3-3-10 mg/kg for normalized total time spent in seizure (B), number of seizures (C) and seizure length (D). Pre-treatment with the selective 5-HT_2CR antagonist SB2402084 (0.5 mg/kg) partially blocked the effect of CP-809,101 (3 mg/kg) on the three seizures parameters. (E) Representative EEG traces for GAERS injected i.p. with vehicle, 3 mg/kg lorcaserin and 3 mg/kg lorcaserin following pre-treatment with SB242084 (0.5 mg/kg, i.p.) (interruption in each trace indicates time of injection). Dose response curves of lorcaserin (right side of the figure) at 0.3-3-10 mg/kg for normalized total time spent in seizure (F), number of seizures (G) and seizure length (H). Pre-treatment with the selective 5-HT_2CR antagonist SB2402084 (0.5 mg/kg) partially blocked the effect of CP-809,101 (3 mg/kg) on the three seizures parameters. All values are normalized to the control period (−40 to 0 min), and are expressed as a percentage of their respective vehicle group for clarity. Values represent mean ± SEM. Time zero indicates the time of injection of the agonist, while the antagonist SB2402084 was injected 10 min before the agonist administration. Asterisks indicates p < 0.05 for a given time bin in the treatment group vs the corresponding time bin in the vehicle group (two-way ANOVA, Sidak's multiple comparison test). CP-809,101 (0.3–10 mg/kg): n = 10–6; CP-809,101(3 mg/kg) ± SB242084 (0.5 mg/kg): n = 10; lorcaserin (0.3–10 mg/kg): n = 8–6; lorcaserin (3 mg/kg) ± SB242084 (0.5 mg/kg): n = 9.